EnteroMedics (RSLS) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of EnteroMedics (NASDAQ:RSLS) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

According to Zacks, “ReShape Lifesciences Inc. is a developer of invasive medical devices to treat obesity and metabolic diseases. The company’s portfolio includes vBloc System(R), ReShape(R) and Gastric Vest System (TM). ReShape Lifesciences Inc., formerly known as EnteroMedics Inc., is based in CA, United States. “

Separately, ValuEngine raised EnteroMedics from a strong sell rating to a sell rating in a research report on Friday, September 1st.

Shares of EnteroMedics (NASDAQ RSLS) traded up $0.02 during trading hours on Wednesday, reaching $1.45. The company’s stock had a trading volume of 344,543 shares, compared to its average volume of 1,604,493. EnteroMedics has a fifty-two week low of $1.23 and a fifty-two week high of $30.41.

EnteroMedics (NASDAQ:RSLS) last announced its earnings results on Tuesday, November 14th. The medical device company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.77). The firm had revenue of $0.36 million during the quarter. EnteroMedics had a negative return on equity of 104.23% and a negative net margin of 4,509.61%. equities analysts anticipate that EnteroMedics will post -1.97 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “EnteroMedics (RSLS) Downgraded to “Sell” at Zacks Investment Research” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3080388/enteromedics-rsls-downgraded-to-sell-at-zacks-investment-research.html.

EnteroMedics Company Profile

ReShape Lifesciences Inc, formerly EnteroMedics Inc, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.